Eventide Asset Management Reports 13.4% Stake in Beta Bionics, Inc. (BBNX)

On May 15, 2026, Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, filed a Schedule 13G/A reporting a 13.4% ownership stake in Beta Bionics, Inc. (BBNX). The filing indicates that Eventide beneficially owns 5,945,488 shares of common stock as of March 31, 2026. This position is held through various entities, primarily the Eventide Gilead Fund, which holds 3,750,973 shares (8.5%), and the Eventide Healthcare & Life Sciences Fund, which holds 2,052,176 shares (4.6%). Additionally, separately managed accounts hold 142,339 shares (0.3%). This filing represents an increase from a previously reported 0.0% ownership, establishing a significant new position in the company. Eventide Asset Management serves as the investment adviser for these funds and accounts, while Kuruvilla and John share voting and dispositive power. The filing was made under Rule 13d-1(b), certifying that the shares were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer.